Skip to main content

Table 2 Lipids and other biomarkers at baseline and at 3 and 6 months after the ezetimibe therapy

From: Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia

Parameters

Pre

Post 3M

Post 6M

Body mass index (kg/m2)

27.9 ± 3.5

27.5 ± 3.4***

27.6 ± 3.4*

Waist circumference (cm)

93.6 ± 8.5

91.8 ± 7.8***

91.5 ± 7.9***

Systolic blood pressure (mmHg)

128.7 ± 14.8

127.2 ± 13.9

127.0 ± 13.0

Diastolic blood pressure (mmHg)

76.0 ± 9.4

75.6 ± 9.4

74.4 ± 10.3

Total cholesterol (mg/dl)

236.2 ± 34.7

208.9 ± 31.9***

207.0 ± 34.5***

LDL-cholesterol (mg/dl)

147.9 ± 29.5

125.5 ± 25.9***

126.5 ± 30.5***

HDL-cholesterol (mg/dl)

51.7 ± 10.7

52.7 ± 10.3

54.5 ± 9.8***

Non HDL-cholesterol (mg/dl)

184.5 ± 30.7

156.2 ± 29.1***

151.9 ± 32.6***

Triglycerides+ (mg/dl)

162.4

145.5*

134.3***

RLP-cholesterol+ (mg/dl)

6.6

5.2***

4.7***

Free fatty acid+ (mEq/l)

437.0

454.8

483.0

Plasma glucose (mg/dl)

106.4 ± 28.8

107.3 ± 24.5

103.3 ± 24.1

Insulin+ (μU/ml)

11.9

11.1

10.0*

HOMA index+

3.1

2.8

2.6

hsCRP+ (mg/dl)

765.1

820.6

871.3

Aldosterone (pg/dl)+

90.9

97.5

96.5

HGF (ng/ml)

0.32 ± 0.06

0.31 ± 0.04

0.30 ± 0.03*

Adiponectine (μg/ ml)+

2.58

2.64

2.53

EPA/AA+

0.31

0.31

0.31

  1. *: p < 0.05, ***: p < 0.001.
  2. Data are means (SD), geometric mean and range. *: These variables are shown in the original scale after analysis using log (natural)-transformed values.
  3. Abbreviations: RLP Remnant-like particle cholesterol, HOMA Homeostasis model assessment, HGF Hepatocyte growth factor, EPA/AA Eicosapentaenoic acid to arachidonic acid.